Lyra Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Lyra Therapeutics Inc LYRA.OQ reported a quarterly adjusted loss of $5.51​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-37.00. The mean expectation of four analysts for the quarter was for a loss of $6.02 per share. Wall Street expected results to range from $-7.50 to $-4.55 per share.

• Revenue fell 69.4% to $183.00 thousand from a year ago; analysts expected $171.25 thousand.

• Lyra Therapeutics Inc's reported EPS for the quarter was a loss of $5.51​.

• The company reported a quarterly loss of $7.44 million.

• Lyra Therapeutics Inc shares had fallen by 25.6% this quarter and lost 35.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 7.4% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."

• Wall Street's median 12-month price target for Lyra Therapeutics Inc is $23.00, about 71% above its last closing price of $6.67

This summary was machine generated from LSEG data August 12 at 08:18 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)